Rash from EGFR inhibitors: Opportunities and challenges for palliation

Current Oncology Reports

Volumn 10, Issue 4, 2008, Pages 304-308

  Solomon, Benjamin M ^a   Jatoi, Aminah ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CLINDAMYCIN; CYCLOSPORIN A; DIPHENHYDRAMINE; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HYDRAZINE; HYDROCORTISONE; MENADIONE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; TACROLIMUS; TETRACYCLINE; PROTEIN KINASE INHIBITOR;

ACNE; ANTIINFLAMMATORY ACTIVITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE PREDISPOSITION; DISTRESS SYNDROME; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; ENZYME ACTIVATION; FOLLICULITIS; HAIR DISEASE; HUMAN; HYPERPIGMENTATION; INCIDENCE; LUNG NON SMALL CELL CANCER; MALE TYPE ALOPECIA; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PATIENT COMPLIANCE; PRIMARY PREVENTION; PUSTULE; REVIEW; TELANGIECTASIA; TREATMENT OUTCOME; TRICHOMEGALY; XEROSIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; LUNG TUMOR; PALLIATIVE THERAPY; RASH;

EXANTHEMA; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 56149086186     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0048-1     Document Type: Review

References (26)

1. Giusti RM, Shastri KA, Cohen MH, et al.: FDA drug approval summary: panitumumab. Oncologist 2007, 12:577-583.
2. Johnson JR, Cohen M, Sridhara R, et al.: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005, 11:6414-6421.
3. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
4. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer. Cancer Biol Ther 2006, 5:340-342.
5. Patiyil S, Chan SNA Jatoi A: New agents, new rashes: an update on skin complications from cancer chemotherapy. Curr Oncol Rep 2006, 8:269-274.
6. Lacouture ME, Basti S, Patel J, Benson A: The SERIES clinic: interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006, 4:236-238.
7. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006, 6:803-812.
8. Kardaun SH, van Duinen KF: Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol 2008, 33:46-49.
9. Galimont-Collen AF, Vos LE, Lavrijsen AP, et al.: Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007, 48:845-851.
10. Kris M, Natale RB, Herbst RS, et al.: Efficacy of gefinitib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003, 290:2149-2158.
11. Saltz LB, Meropol NJ, Loehrer PJ, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
12. Lai SE, Minnelly L, O'Keefe O, et al.: Influence of skin color in the development of erlotinib-induced rash: A report from the SERIES clinic [ASCO abstract 9127]. J Clin Oncol 2007, 25(18S):9127.
13. Busam KJ, Capodieci C, Motzer R, et al.: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001, 144:1169-1176.
14. Va Doorn R, Kirtschig G, Scheffer E, et al.: Follicular and epidermal alterations in patients treated with ZD1839, an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002, 147:598-601.
15. Wacker B, Nagrani T, Weinberg J, et al.: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13:3913-3921.
16. Wagner LI, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Oncology 2007, 21:34-36.
17. Barankin B, DeKoven J: Psychosocial effect of common skin diseases. Can Fam Physician 2002, 48:712-716.
18. Lasek RJ, Chren MM: Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998, 134:454-458.
19. Scope A, Agero AL, Dusza SW, et al.: Randomized double blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007, 25:5390-5396.
20. Jatoi A, Rowland K, Sloan JA, et al.: Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash [ASCO abstract LBA9006]? J Clin Oncol 2007, 25(18S):LBA9006.
21. Luu M, Lai SE, Patel J, et al.: Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 2007, 23:42-45.
22. Perez-Soler R, Zou Y, Li T, et al.: Topical vitamin K3 (Vit K3, menadione) prevents erlotinib and cetuximab-induced EGFR inhiition in the skin [ASCO abstract 9127]. J Clin Oncol 2006, 24(18S):9127.
23. Perez-Soler R, Zou Y, Li T, Ling Y: Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib (E) in human skin keratinocytes whereas vit K3 exerts a protective effect: implications for the management of the skin rash [ASCO abstract 9124]. J Clin Oncol 2007, 25(18S):9124.
24. Beier JI, von Montfort C, Sies H, Klotz LO: Activation of ErbB2 by 2-methyl-1,4-naphthoquinone (menadione) in human keratinocytes: Role of EGFR and protein tyrosine phosphatases. FEBS Lett 2006, 580:1859-1864.
25. Yoshikawa K, Nigorikawa K, Tsukamoto M, et al.: Inhibition of PTEN and activation of Akt by menadione. Biochim Biophys Acta 2007; 1770:687-693.
26. Klotz LO, Patak P, Ale-Agha N, et al.: 2-methyl-1,4-naphthoquinone, vitamin K3, decreases gap junctional intercellular communication via activation of the epidermal growth factor receptor/extracellular signal-regulated kinase cascade. Cancer Res 2002, 62:4922-4928.